DrugBank, an Edmonton, Canada-based provider of a drug knowledge platform, announced that it secured $9 million in seed funding.
The round was led by Brightspark Ventures, with participation from Amplitude Ventures, Theodorus Investment Funds, and existing investors including AccelerateFund and Milad Alucozai from BoxOne Ventures.
With this funding, DrugBank will rapidly scale its operations and invest in research and development. Also plan to expand its AI-powered technologies to more effectively solve major industry problems.
Company: OMx Personal Health Analytics Inc.
Round: Seed Round
Funding Month: April 2022
Lead Investors: Brightspark Ventures
Additional Investors: Amplitude Ventures, Theodorus Investment Funds, AccelerateFund, and Milad Alucozai
Company Website: https://www.drugbank.com/
Software Category: Drug Knowledge Platform
About the Company: DrugBank is the world’s first intelligent and comprehensive drug knowledge platform. DrugBank utilizes artificial intelligence, their team of experts gathers, authors, verifies, and structures the latest biomedical information into one knowledge platform. This platform is accessible through DrugBank Online (their free-to-use website) and data and software integrations. DrugBank is honored to partner with the world’s leading biomedical researchers as they pursue their goal of better medical outcomes.